Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.49 +0.68%
Revenue Growth %: +91.8%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +91.8%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.96), $0.22 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $45.4 million versus the consensus estimate of $57.27 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Creatd files Form S-1 and reports Q1 2026 financial results
- Qualcomm investor day to detail data center plans Wednesday
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
